Navigation Links
CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
Date:4/1/2008

LAS VEGAS, April 1, 2008 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has appointed Nabil Dib, M.D., M.Sc., F.A.C.C., as the Principal Investigator for its Phase II clinical trial in patients with severe coronary heart disease.

Dr. Dib is currently the Director of Cardiovascular Research at Catholic Healthcare West's Chandler Regional Medical Center and Mercy Gilbert Medical Center in Arizona, as well as the Assistant Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy at the University of California, San Diego. He is also President of the International Society for Cardiovascular Translational Research, La Jolla, Calif., and an international expert on the treatment of heart failure and coronary artery disease. Dr. Dib has extensive experience directing clinical trials, particularly in the arena of examining agents which stimulate the growth of new blood vessels in a damaged heart.

In previous clinical studies, Dr. Dib has pioneered the use of the NOGA(R) XP mapping system and the MyoStar(TM) injection catheter. These two devices will be used in CVBT's Phase II heart trial, in which the potent angiogenic protein human Fibroblast Growth Factor -1 (FGF-1) will be injected into patients' hearts. Dr. Dib serves as the principal trainer for all interventional cardiologists who wish to receive training on the NOGA XP system or MyoStar injection catheter, and will work closely with the other clinical investigators in CVBT's Phase II heart trial to ensure the safe and accurate injection of FGF-1 into the heart.

"We are extremely excited to welcome a cardiologist and clinical researcher of Dr. Dib's caliber to lead our Phase II heart study," said Thomas J. Stegmann, M.D., co-founder and co-president of CVBT. "His expertise with the NOGA XP and MyoStar devices, and his strong relationships with leading interventional cardiologists throughout the world will be invaluable to our clinical effort to establish FGF-1 as the treatment of choice for severe angina and coronary heart disease."

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials underway in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional trial is also being conducted in patients with chronic back pain who may have perfusion defects to their spine.

About Catholic Healthcare West

Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and one of the largest not-for-profit hospital providers in the West. Founded in 1986, the CHW network of more than 8,500 physicians and approximately 50,000 employees serve a population spanning 22 million people at 43 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In fiscal year 2007, CHW provided $922 million in charity care, community benefits, and unreimbursed patient care. CHW facilities in Arizona include Chandler Regional Medical Center, Mercy Gilbert Medical Center, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, CHW Urgent Cares in Ahwatukee, Gilbert and Queen Creek, Sun Lakes Laboratory, Warner Outpatient Surgery and the Arizona Orthopedic Surgical Hospital. For more information, please visit our Website at http://www.chwHEALTH.org.

About Chandler Regional Medical Center

Chandler Regional Medical Center is a 225-bed, acute-care, non-for-profit provider of emergency care, maternal child services, cardiovascular services, wound healing, cancer treatment, diabetes treatment, and diagnostic services. It is located at 475 S. Dobson Road (corner of Dobson Road and Frye Road) in Chandler. For more information, please visit http://www.chandlerregional.org or call (480) 728-3000. Chandler Regional Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-3424. For information on physician referrals or community classes and support groups, please contact the ResourceLink toll-free at 1.877.728.5414 or resourcelink@chw.edu.

About Mercy Gilbert Medical Center

Mercy Gilbert Medical Center is located at the intersection of Val Vista Drive and Loop 202 (south of Pecos Road and east of Val Vista Drive). Mercy Gilbert Medical Center is a four-story, full-service acute-care facility with 182 beds. For more information, please visit http://www.mercygilbert.org or call (480) 728-8000. Mercy Gilbert Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-8396. For information on physician referrals or community classes and support groups, please contact the ResourceLink toll-free at 1.877.728.5414 or resourcelink@chw.edu.

CardioVascular BioTherapeutics, Inc.

Allison Lipson, (702) 839-7200

alipson@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. West Pharmaceutical Services, Inc. Appoints New Director
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
6. Clinical Trial Participation Unaffected by Disclosure of Investigators Financial Stake, Food and Drug Law Journal Article Finds
7. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... -- Bayer has awarded grants totaling more than $2 million to ... Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers ... and Uniformed Services University of the Health Sciences in ... were announced last night during a reception at the International ... Berlin, Germany . ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... Shamanic Teacher ... and Spiritual Awakening, is proud to announce the return of her increasingly ... interested in learning more about the mystical world of shamanism, nature wisdom, the ...
(Date:7/27/2017)... ... July 27, 2017 , ... Standard Process is ushering in a new ... the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a ... the fall of this year, occupying over 10,000 square feet on the first floor ...
(Date:7/27/2017)... ... July 27, 2017 , ... Somnoware, a leading ... (PSG) distributed scoring solution to its healthcare management platform. This solution provides physicians ... speed and functionality of scoring in the cloud is on par with doing ...
(Date:7/27/2017)... ... ... eating isn’t always easy. Currently, more than 80 percent of Americans fail to eat the ... and sugar. This trend may help explain why the obesity rate seems stuck. The most ... a culture, we seem to have food on the brain more. "We eat two more ...
(Date:7/27/2017)... NY (PRWEB) , ... July 27, 2017 , ... ... President Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS Healthcare ... event kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel ...
Breaking Medicine News(10 mins):